The common therapies for CRVO treatment are laser photocoagulation for peripheral ischemia, macular laser for ME (occasionally) and intravitreal injections of anti-VEGF and steroids, which are used to ...
The trials are evaluating DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).
The MHRA has granted marketing authorisation for Eylea® (aflibercept 8 mg) for the treatment of patients with macular oedema following retinal vein occlusion (RVO) including branch, central and ...
Patients with diabetic macular edema can expect similar BCVA improvements and CST reductions using an aflibercept biosimilar compared with conventional aflibercept. An aflibercept biosimilar is ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. KOLOA, Hawaii — In this expert perspective from Hawaiian ...
Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...
Real-world evidence links higher injection frequency to better VA outcomes and reduced CST fluctuations, reinforcing durability as a primary unmet need in nAMD and DME management.
TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results